Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...
Yahoo Finance6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...
Investopedia6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.
Madison.com6d
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...